Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Affymetrix

Executive Summary

Affymetrix: Firm is negotiating with Glaxo to become an independent entity, Affymetrix President and CEO David Singer tells Alex. Brown Health Care Seminar May 16 in Baltimore. Glaxo assumed Affymax' 65% interest in Affymetrix when it acquired Affymax in January ("The Pink Sheet" Jan. 30, p. 12). Affymetrix has retained independent operations since the Glaxo acquisition. Glaxo and Affymetrix are currently exploring the possibility of a genomics collaboration, Singer indicated...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026270

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel